Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Bought by Hussman Strategic Advisors Inc.

Hussman Strategic Advisors Inc. boosted its stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 33.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 84,000 shares of the company's stock after acquiring an additional 21,000 shares during the period. Harmony Biosciences comprises approximately 0.9% of Hussman Strategic Advisors Inc.'s portfolio, making the stock its 25th largest position. Hussman Strategic Advisors Inc. owned approximately 0.15% of Harmony Biosciences worth $2,890,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of HRMY. CWM LLC lifted its holdings in shares of Harmony Biosciences by 111.7% in the 3rd quarter. CWM LLC now owns 1,469 shares of the company's stock valued at $59,000 after purchasing an additional 775 shares during the last quarter. Creative Planning acquired a new position in Harmony Biosciences during the third quarter worth about $246,000. Hennion & Walsh Asset Management Inc. increased its holdings in Harmony Biosciences by 20.8% in the third quarter. Hennion & Walsh Asset Management Inc. now owns 54,274 shares of the company's stock valued at $2,171,000 after buying an additional 9,329 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Harmony Biosciences by 21.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,056 shares of the company's stock valued at $80,000 after acquiring an additional 360 shares during the period. Finally, Nisa Investment Advisors LLC boosted its stake in shares of Harmony Biosciences by 8,867.7% during the 3rd quarter. Nisa Investment Advisors LLC now owns 5,560 shares of the company's stock worth $222,000 after acquiring an additional 5,498 shares in the last quarter. Institutional investors and hedge funds own 86.23% of the company's stock.

Analysts Set New Price Targets

HRMY has been the subject of several research reports. HC Wainwright reaffirmed a "buy" rating and set a $75.00 price objective on shares of Harmony Biosciences in a report on Wednesday, February 19th. Needham & Company LLC decreased their price objective on shares of Harmony Biosciences from $52.00 to $50.00 and set a "buy" rating on the stock in a research report on Wednesday, February 19th. Cantor Fitzgerald raised their target price on shares of Harmony Biosciences from $51.00 to $58.00 and gave the company an "overweight" rating in a report on Wednesday, October 30th. Mizuho lowered their target price on Harmony Biosciences from $52.00 to $42.00 and set an "outperform" rating on the stock in a report on Thursday. Finally, Oppenheimer reiterated an "outperform" rating and set a $59.00 price target (up from $56.00) on shares of Harmony Biosciences in a report on Wednesday, October 30th. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $53.67.

Harmony Biosciences Trading Down 0.8 %

HRMY stock traded down $0.29 during trading on Monday, reaching $34.28. 405,790 shares of the stock traded hands, compared to its average volume of 574,793. The firm has a market capitalization of $1.95 billion, a PE ratio of 16.39, a P/E/G ratio of 0.47 and a beta of 0.80. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.24 and a quick ratio of 3.20. The business's 50 day moving average price is $36.57 and its 200-day moving average price is $35.81. Harmony Biosciences Holdings, Inc. has a 52-week low of $28.14 and a 52-week high of $41.61.

Insider Transactions at Harmony Biosciences

In other news, insider Jeffrey Dierks sold 10,507 shares of the company's stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $37.01, for a total value of $388,864.07. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Sandip Kapadia sold 25,000 shares of the company's stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $40.18, for a total transaction of $1,004,500.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 72,452 shares of company stock worth $2,831,679. 30.80% of the stock is currently owned by company insiders.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.